Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Johnson and Johnson
McKesson
Mallinckrodt
Boehringer Ingelheim

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Daiichi Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Daiichi

Drugs and US Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo Inc TURALIO pexidartinib hydrochloride CAPSULE;ORAL 211810-001 Aug 2, 2019 RX Yes Yes   Start Trial   Start Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No   Start Trial   Start Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes 9,149,532   Start Trial Y   Start Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Daiichi

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Daiichi Sankyo TRIBENZOR amlodipine besylate; hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 200175-004 Jul 23, 2010 5,616,599*PED   Start Trial
Daiichi Sankyo BENICAR HCT hydrochlorothiazide; olmesartan medoxomil TABLET;ORAL 021532-002 Jun 5, 2003 5,616,599*PED   Start Trial
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-002 Oct 2, 2009 5,917,007*PED   Start Trial
Daiichi Sankyo WELCHOL colesevelam hydrochloride FOR SUSPENSION;ORAL 022362-001 Oct 2, 2009 5,693,675*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for DAIICHI drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Powder for Oral Suspension 1.875 g/Packet and 3.75 g/Packet ➤ Subscribe 2010-04-09
➤ Subscribe Tablets 10 mg/20 mg and 5 mg/40 mg ➤ Subscribe 2008-03-31
➤ Subscribe Tablets 20 mg/12.5 mg ➤ Subscribe 2007-05-11
➤ Subscribe Capsules 30 mg ➤ Subscribe 2009-02-27
➤ Subscribe Tablets 15 mg, 30 mg and 60 mg ➤ Subscribe 2019-01-28
➤ Subscribe Tablets 625 mg ➤ Subscribe 2009-07-01
➤ Subscribe Tablets 5 mg/20 mg and 10 mg/40 mg ➤ Subscribe 2008-02-11
➤ Subscribe Tablets 5 mg, 20 mg and 40 mg ➤ Subscribe 2006-04-25
➤ Subscribe Tablets 40 mg/12.5 mg and 40 mg/25 mL ➤ Subscribe 2007-02-15
➤ Subscribe Tablets 15 mg, 30 mg, 60 mg and 100 mg ➤ Subscribe 2019-01-28

Supplementary Protection Certificates for Daiichi Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0454511 99C0009 Belgium   Start Trial PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
1405852 2015/045 Ireland   Start Trial PRODUCT NAME: EDOXABAN, A SALT THEREOF, A SOLVATIC THEREOF, OR AN N-OXIDE THEREOF, IN PARTICULAR EDOXABAN TOSYLATE; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
2140867 PA2018005,C2140867 Lithuania   Start Trial PRODUCT NAME: EDOKSABANAS, JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, ARBA BET KURIO IS JU HIDRATAS, YPAC EDOKSABANO P-TOLUENSULFONATO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
1405852 122015000077 Germany   Start Trial PRODUCT NAME: EDOXABAN, DESSEN SALZ, DESSEN SOLVAT, ODER DESSEN N-OXID, INSBESONDERE EDOXABANTOSILAT; REGISTRATION NO/DATE: EU/1/15/993/001-028 20150619
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Merck
Dow
Baxter
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.